MedTrace Logo

Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency

NCT03114020 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2020-04-21

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and efficacy of administering repeated doses of Hyaluronic Acid Inhalation Solution to subjects with Emphysema that have Alpha-1-Antitrypsin deficiency

Conditions

Interventions

DRUG

Hyaluronic Acid Inhalation Solution

twice a day 3 mL of 0.03% Hyaluronic Acid Inhalation Solution

DRUG

Placebo Inhalation Solution

Twice a day 3 ml of placebo inhalation solution

Sponsors & Collaborators

  • Gerard Turino

    lead INDIV

Principal Investigators

  • Gerard M Turino, MD · Mount Sinai St Lukes

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-22
Primary Completion
2019-11-12
Completion
2019-11-12
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03114020 on ClinicalTrials.gov